{"id":"W4404581096","doi":"10.1016/s0140-6736(24)01762-8","title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"Daiichi Sankyo Europe; Genentech; Sun Pharma; Mitsubishi Tanabe Pharma Corporation; Celltrion; Boston Pharmaceuticals; Kissei; Boston Scientific Corporation; Teva Pharmaceutical Industries; Janssen Pharmaceuticals; EA Pharma Co., Ltd.; Gilead Sciences; GlaxoSmithKline; Amgen; Kyorin Pharmaceutical; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ustekinumab; Placebo; Internal medicine; Crohn's disease; Clinical trial; Clinical endpoint; Ulcerative colitis; Adverse effect; Phases of clinical research; Randomized controlled trial; Colonoscopy; Gastroenterology; Inflammatory bowel disease; Surgery; Disease; Adalimumab; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002032511,0.001452389,0.004003517,0.0004439087,0.0005430218,0.001127582,0.000806344,0.00218047,0.00329284],"category_scores_gemma":[0.00155468,0.000829562,0.002216302,0.0004294903,0.001297465,0.001348496,0.0003732907,0.003082814,0.0008252611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000571405,"about_ca_system_score_gemma":0.0007793271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005367655,"about_ca_topic_score_gemma":0.001052055,"domain_scores_codex":[0.9993545,0.000329996,0.00004480613,0.00008947832,0.00005777397,0.0001233547],"domain_scores_gemma":[0.9990381,0.0002647877,0.0002110869,0.00007440012,0.00005807708,0.0003535953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9665239,0.005619481,0.001256052,0.0005269886,0.000873067,0.00006343213,0.00008353047,0.0002475339,0.008602756,0.0000544057,0.0005063078,0.01564248],"study_design_scores_gemma":[0.8941163,0.09767334,0.00601388,0.00002515331,0.0005452526,0.00006611051,0.00003140092,0.0002925474,0.0006501211,0.00009432749,0.0004658378,0.00002580035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990895,0.005524655,0.0004568665,0.0004962449,0.0002385047,0.0008937244,0.0004332794,0.00008388437,0.0009778386],"genre_scores_gemma":[0.9932899,0.002053177,0.0008739854,0.0008661401,0.0002700618,0.0008508841,0.0006118086,0.00002537861,0.001158577],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004003517,"threshold_uncertainty_score":0.01101559,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01430349561427385,"score_gpt":0.2855391879197301,"score_spread":0.2712356923054562,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}